Jazz Pharmaceuticals PLC

1JAZZ

Company Profile

  • Business description

    Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.

  • Contact

    Waterloo Road
    Fifth Floor, Waterloo Exchange
    DublinD04 E5W7
    IRL

    T: +353 16347800

    E: [email protected]

    https://www.jazzpharmaceuticals.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    2,800

Stocks News & Analysis

stocks

4 ASX shares that could be vulnerable to an August surprise

Any missteps this reporting season could be costly for these shares, which have all risen to lofty valuations.
stocks

Another incredible quarter from Microsoft

We were wrong when we thought last quarter would be hard to top.
stocks

10 best US dividend aristocrats to buy now—including a surprise outperformer

These undervalued stocks with wide and narrow moats have increased their dividends for 25 consecutive years or more.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,917.1081.90-0.91%
CAC 407,546.16225.81-2.91%
DAX 4023,425.97639.50-2.66%
Dow JONES (US)43,588.58542.40-1.23%
FTSE 1009,068.5864.23-0.70%
HKSE24,507.81265.52-1.07%
NASDAQ20,650.13472.31-2.24%
Nikkei 22540,799.60270.22-0.66%
NZX 50 Index12,729.4094.34-0.74%
S&P 5006,238.01101.38-1.60%
S&P/ASX 2008,662.0080.80-0.92%
SSE Composite Index3,559.9513.26-0.37%

Market Movers